Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 35 of 5804
-
New hope for hepatitis delta: phase 3 trial of brelovitug launches
Disease control OngoingThis is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness …
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a pill delay diabetes in kids? new trial hopes so
Prevention Recruiting nowThe purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
Nanocell attack: new combo therapy takes on tough pancreatic cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) w…
Phase: PHASE1, PHASE2 • Sponsor: Engeneic Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New weekly shot could help millions shed pounds and control diabetes
Disease control Recruiting nowThe primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Phase: PHASE3 • Sponsor: Kailera • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a drug combo cure hepatitis b in kids? new trial aims to find out
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with chronic hepatitis B virus infection.
Phase: PHASE4 • Sponsor: Qing-Lei Zeng • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New monthly shot could stop COVID-19 before it starts
Prevention OngoingThe main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is …
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Lab-Grown skin patch could heal wounds in 'Butterfly Children'
Disease control Recruiting nowThis study is being done to find out if a new type of skin graft, called GMEB-SASS, is safe and effective for helping wounds heal in people with RDEB (Recessive Dystrophic Epidermolysis Bullosa). The GMEB-SASS graft contains two types of living skin cells: keratinocytes and fibr…
Phase: PHASE1, PHASE2 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Off-the-Shelf CAR-T cells take on tough blood cancers
Disease control Recruiting nowThis study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It ta…
Phase: PHASE1, PHASE2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Gene therapy hope for babies with rare muscle disease
Disease control Recruiting nowGB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months …
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to turn Chemo-Resistant breast cancer curable
Disease control Recruiting nowThe goal of this clinical trial is to test whether a "rescue" strategy can turn chemotherapy-resistant triple-negative breast cancer (TNBC) into a curable state. Patients whose tumors fail to shrink after 2 cycles of standard neoadjuvant chemotherapy will receive a short, high-pr…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Hard-to-Treat myeloma: phase 3 trial launches
Disease control Recruiting nowThis study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising ALS drug enters final testing phase
Disease control Not yet recruitingThe objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Zipper therapy breakthrough: new combo may boost recovery in rare brain disease
Disease control Recruiting nowStudy Title: A National, Multicenter, Randomized Controlled Trial of the Modified Zipper Therapy in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (ELITE Study) Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of a novel seque…
Phase: PHASE3 • Sponsor: Tianjin Medical University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowA Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Phase: PHASE1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemia
Disease control Not yet recruitingThis is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts. In Phase 2, we are testing three radiation dose levels of 131I-apamistamab combined with fludarabine and low-dose whole-body radiation before …
Phase: PHASE2, PHASE3 • Sponsor: Actinium Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 16:44 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Not yet recruitingThis is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19-IL-15/IL15sushi cCAR T cells in patients with relapsed and/or refractory SLE, with or without Lupus Nephritis.
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Stroke-Clot zapper: new device could save brains within 24 hours
Disease control Not yet recruitingSupernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.
Phase: NA • Sponsor: Gravity Medical Technology, INC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lab-grown heart cells injected into failing hearts: a new hope?
Disease control Not yet recruitingThe purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.
Phase: PHASE1, PHASE2 • Sponsor: Heartseed Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy aims to stop oral cancer from coming back
Disease control Recruiting nowThis is a multicenter, open-label, randomized phase III clinical trial evaluating perioperative treatment with sintilimab combined with chemotherapy in patients with locally advanced oral squamous cell carcinoma. Despite standard treatment with surgery followed by postoperative …
Phase: PHASE3 • Sponsor: Qunxing Li,MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC